ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 116 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $26,841,345 | -41.7% | 5,591,947 | -8.8% | 0.00% | -50.0% |
Q2 2023 | $46,040,348 | -16.9% | 6,130,539 | -50.0% | 0.00% | +33.3% |
Q1 2023 | $55,410,146 | -19.6% | 12,258,882 | +100.5% | 0.00% | -57.1% |
Q4 2022 | $68,898,334 | +55.5% | 6,113,428 | +32.0% | 0.01% | +40.0% |
Q3 2022 | $44,315,000 | +37.4% | 4,630,574 | +16.2% | 0.01% | +66.7% |
Q2 2022 | $32,248,000 | -46.4% | 3,986,214 | +12.0% | 0.00% | -40.0% |
Q1 2022 | $60,147,000 | +7.9% | 3,558,954 | +37.3% | 0.01% | +25.0% |
Q4 2021 | $55,722,000 | -40.1% | 2,592,939 | +105.9% | 0.00% | -42.9% |
Q3 2021 | $93,020,000 | +34.6% | 1,259,416 | -0.4% | 0.01% | +40.0% |
Q2 2021 | $69,114,000 | -25.0% | 1,263,973 | +1.2% | 0.01% | -37.5% |
Q1 2021 | $92,139,000 | +0.0% | 1,249,508 | +16.9% | 0.01% | 0.0% |
Q4 2020 | $92,105,000 | +225.9% | 1,068,499 | +42.7% | 0.01% | +166.7% |
Q3 2020 | $28,261,000 | – | 748,830 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
venBio Partners LLC | 9,699,925 | $46,559,640 | 13.20% |
Vivo Capital, LLC | 4,220,048 | $20,256,230 | 2.22% |
Logos Global Management LP | 1,000,000 | $4,800,000 | 0.64% |
Orbimed Advisors | 2,871,000 | $13,780,800 | 0.29% |
Redmile Group, LLC | 1,283,289 | $6,159,787 | 0.29% |
BRAIDWELL LP | 1,249,900 | $5,999,520 | 0.19% |
Cormorant Asset Management, LP | 612,079 | $2,937,979 | 0.17% |
Nan Fung Group Holdings Ltd | 41,950 | $201,360 | 0.16% |
Forefront Analytics, LLC | 13,769 | $66,092 | 0.04% |
CORNERCAP INVESTMENT COUNSEL INC | 35,071 | $168,341 | 0.03% |